Achillion is not likely to develop an all-oral Hep C therapy on its own, which is why the company needs to be as deal friendly as possible.
"None of the major players in the Hep C field can lay claim today to having everything they need," said Kishbauch, explaining why he thinks Hep C deal activity is about to accelerate.
He's right. The big Hep C players -- Roche, Merck, Vertex, Bristol-Myers Squibb (BMY) -- could all benefit from bringing in new drugs. It remains to be seen, however, if Achillion has what these guys want.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.